# William J Gibson

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 14 papers | 1,860 citations | 759233 12 h-index | 996975 15 g-index |
| 16 all docs | 16 docs citations | 16 times ranked | 4378 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. Journal of Thrombosis and Thrombolysis, 2020, 49, 1-9. | 2.1 | 36 |
| 2 | Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nature Communications, 2020, 11, 2517. | 12.8 | 60 |
| 3 | PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 334-345. | 7.0 | 17 |
| 4 | Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2018, 72, 129-136. | 2.8 | 12 |
| 5 | SWELL1 is a regulator of adipocyte size, insulin signalling and glucose homeostasis. Nature Cell Biology, 2017, 19, 504-517. | 10.3 | 111 |
| 6 | Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports, 2016, 6, 25521. | 3.3 | 13 |
| 7 | The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics, 2016, 48, 848-855. | 21.4 | 174 |
| 8 | MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282. | 21.4 | 214 |
| 9 | EGLN1 Inhibition and Rerouting of Î±-Ketoglutarate Suffice for Remote Ischemic Protection. Cell, 2016, 164, 884-895. | 28.9 | 108 |
| 10 | ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genetics, 2015, 208, 345-350. | 0.4 | 73 |
| 11 | Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget, 2015, 6, 1327-1339. | 1.8 | 50 |
| 12 | BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925. | 7.0 | 296 |
| 13 | Response to Letter Regarding Article, â€œStent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatingsâ€• Circulation, 2011, 124, . | 1.6 | 2 |
| 14 | Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings. Circulation, 2011, 123, 1400-1409. | 1.6 | 688 |